|
시장보고서
상품코드
2043692
멀티플렉스 어세이 시장 예측(-2031년) : 제품 및 서비스별, 유형별, 기술별, 용도별, 최종사용자별, 지역별Multiplex Assays Market by Product & Service (Consumable, Instrument), Type (Protein, Nucleic Acid), Technology (Flow Cytometry), Application, End User (Hospital, Research Institute)-Global Forecast to 2031 |
||||||
멀티플렉스 어세이 시장 규모는 2026년에는 약 71억 5,000만 달러 규모에 달하며, 2031년까지 106억 5,000만 달러에 달할 것으로 예측되고 있으며, CAGR은 8.3%에 달할 전망입니다.
이러한 꾸준한 성장은 의료 기관이 조기 진단, 정확한 바이오마커 및 환자 결과 개선에 점점 더 집중하고 있기 때문입니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 대상 단위 | 금액(10억 달러) |
| 부문 | 제품·서비스별, 유형별, 기술별, 용도별, 최종사용자별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 중동 및 아프리카, 라틴아메리카 |
질병의 복잡성 증가, 맞춤형 의료의 부상, 효율적인 고처리량 검사법에 대한 요구 등이 멀티플렉스 분석에 대한 글로벌 수요 증가를 견인하고 있습니다.
"제품 및 서비스별로는 소모품 부문이 예측 기간 중 가장 높은 CAGR을 나타낼 것으로 예상됩니다. "
이 부문의 성장은 주로 분석 수행에 필수적인 멀티플렉스 분석 키트, 시약, 비드, 프라이머, 프로브 및 컨트롤에 대한 지속적인 수요에 의해 주도되고 있습니다. 감염성 질환, 암, 자가면역질환의 발병률 증가로 인해 다양한 의료현장에서의 검사 수요가 증가할 것으로 예상됩니다. 이에 따라 병원, 진단검사실, 연구시설에서 이 부문의 수요가 확대될 것으로 보입니다. 또한 다중 검사 프로토콜의 사용 확대와 새로운 분석법 개발도 이러한 성장에 더욱 기여할 것으로 예상됩니다.
"기술별로 보면 2026년에는 유세포분석 부문이 멀티플렉스 분석 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. "
이 시장 부문이 선도적인 위치를 차지하고 있는 이유는 병원 및 검사기관에서 이 기술의 보급으로 바이오마커 및 세포 분석에서 민감도, 정확도, 재현성이 향상된 고처리량 및 다중 매개변수 검사가 가능해졌기 때문입니다. 유세포분석은 한 번의 검사로 여러 마커를 빠르게 분석할 수 있으며, 면역학, 종양학, 중개연구에서 가장 널리 사용되는 기기 중 하나입니다. 유세포분석기에 대한 수요는 주로 진단 검사 및 과학 연구의 증가와 질병 프로파일링 및 치료 모니터링의 필요성에 의해 주도되고 있습니다.
"아시아태평양은 멀티플렉스 분석 시장에서 가장 높은 성장률을 기록할 것으로 예상됩니다. "
이 지역은 의료시설의 확충과 의료비 증가 등 여러 요인으로 인해 빠른 성장을 보이고 있습니다. 병원, 검사실, 진단센터의 현대화도 이러한 성장에 기여하고 있습니다. 또한 감염성 질환, 암, 만성질환의 발생률 증가가 고급 진단 검사에 대한 수요를 견인하고 있습니다. 또한 생명공학 연구에 대한 투자 확대, 제약 생산 시설의 확장 및 진단 센터의 증가는 아시아태평양의 멀티플렉스 분석의 성장을 촉진하고 있습니다. 이 시장의 성장에 기여하는 주요 국가로는 중국, 인도, 일본, 한국 등이 있습니다.
멀티플렉스 어세이 시장의 주요 기업은 Thermo Fisher Scientific, Inc.(미국), Illumina, Inc.(미국), Bio-Rad Laboratories, Inc.(미국), QIAGEN N.V.(네덜란드), Danaher Corporation(미국), Becton, Dickinson and Company(미국), Merck KGaA(독일), DiaSorin S.p.A.(이탈리아), Revvity, Inc.(미국), F. Hoffmann-La Roche Ltd.(스위스), Agilent Technologies(미국), Quanterix Corporation(미국), bioMerieux(프랑스)입니다.
조사 범위:
본 조사 리포트에서는 멀티플렉스 어세이 시장을 제품·서비스(소모품, 기기, 소프트웨어·서비스), 유형(단백질 멀티플렉스 어세이, 핵산 멀티플렉스 어세이, 세포 기반 멀티플렉스 어세이), 기술(유세포분석, 형광 탐지, 멀티플렉스 실시간 PCR, 루미네 센스, 차세대 시퀀싱(NGS), 기타 기술), 용도(연구개발, 임상 진단), 최종사용자(제약·바이오테크놀러지 기업, 병원·진단 검사 기관 , 학술·연구기관, 수탁 연구기관, 기타 최종사용자) 및 지역(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카)으로 분류하고 있습니다.
이 보고서의 조사 범위는 멀티플렉스 분석 시장의 성장에 영향을 미치는 주요 요인(촉진요인, 저해요인, 기회, 과제 등)에 대한 상세한 정보를 포함하고 있습니다. 이 보고서는 주요 업계 플레이어에 대한 상세한 분석을 통해 사업 개요, 솔루션, 파트너십, 제휴, 사업 확장, 계약, 신제품 출시 및 멀티플렉스 분석 시장의 최근 동향과 같은 주요 전략에 대한 인사이트를 제공합니다. 이 보고서에서는 멀티플렉스 분석 시장 생태계에서 부상하고 있는 스타트업 기업의 경쟁 분석도 다루고 있습니다.
이 보고서를 구매해야 하는 이유:
이 보고서는 전체 멀티플렉스 분석 시장과 그 하위 부문의 매출에 대한 가장 정확한 추정치를 제공함으로써 시장 리더와 신규 진입자에게 도움이 될 것입니다. 이 보고서는 이해관계자들이 경쟁 상황을 이해하고, 더 심층 인사이트를 얻고, 자신의 비즈니스를 적절히 포지셔닝하고, 적절한 시장 진입 전략을 수립하는 데 도움이 될 것입니다. 또한 이 보고서는 이해관계자들이 시장 동향을 파악하고 주요 촉진요인, 억제요인, 기회 및 과제에 대한 정보를 제공함으로써 시장 동향을 파악할 수 있도록 돕습니다.
이 보고서에서는 다음과 같은 사항에 대한 인사이트를 제공합니다. :
- 주요 촉진요인(만성질환 및 감염성 질환의 발생률 증가, 싱글플렉스 및 기존 분석법 대비 우월성, 동반진단에서 멀티플렉스 분석법 활용 확대, 질병 조기 발견에 대한 관심 증가, 만성질환 및 감염성 질환 발생률 증가), 제약 요인(멀티플렉스 분석 장비 관련 비용 제약, 규제 문제, 엄격한 품질 기준), 기회(분자 및 단백질 기반 진단의 바이오마커 검증 확대, 분자 및 단백질 기반 진단 장비 관련 비용 제약, 규제 문제, 엄격한 품질 기준) 멀티플렉스 분석 기기 관련 비용 제약, 규제 문제 및 엄격한 품질 기준), 기회(분자 진단 및 단백질 기반 진단에서 바이오마커 검증 확대, 분자 진단 및 단백질 진단에서 바이오마커 검증의 발전, 신흥 시장에서의 확대), 도전 과제( 숙련된 전문 인력 부족, 복잡한 데이터 분석 및 해석)에 대해 분석하고 있습니다.
- 제품 개발/혁신: 멀티플렉스 분석 시장의 미래 기술, R&D 활동 및 신제품 출시에 대한 심층적인 인사이트를 제공합니다.
- 시장 개발: 수익성 높은 시장에 대한 종합적인 정보. 이 보고서는 다양한 지역에 걸쳐 다중 분석 시장을 분석합니다.
- 시장 다각화: 멀티플렉스 분석 시장의 신제품, 미개발 지역, 최근 동향 및 투자에 대한 포괄적인 정보를 제공합니다.
경쟁 분석 : Thermo Fisher Scientific, Inc.(미국), Illumina, Inc(미국), Bio-Rad Laboratories, Inc.(미국), DiaSorin S.p.A.(이탈리아), bioMerieux(프랑스) 등 주요 기업의 시장 점유율, 성장 전략, 제품 라인업에 관한 상세한 평가.
자주 묻는 질문
목차
제1장 서론
제2장 개요
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI에 의한 영향, 특허, 혁신, 향후 응용
제7장 규제 상황과 지속가능성 구상
제8장 고객 상황과 구매 행동
제9장 멀티플렉스 어세이 시장(제품·서비스별)
제10장 멀티플렉스 어세이 시장(유형별)
제11장 멀티플렉스 어세이 시장(기술별)
제12장 멀티플렉스 어세이 시장(용도별)
제13장 멀티플렉스 어세이 시장(최종사용자별)
제14장 멀티플렉스 어세이 시장(지역별)
제15장 경쟁 구도
제16장 기업 개요
제17장 조사 방법
제18장 부록
KSAThe market for multiplex assays is projected to be valued at approximately USD 7.15 billion in 2026 and is expected to reach USD 10.65 billion by 2031, reflecting a 8.3% growth rate. This steady growth is driven by medical institutions' growing focus on early diagnosis, accurate biomarkers, and improved patient outcomes.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product & Service, Type, Technology, Application, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Middle East & Africa, Latin America |
Factors such as the increasing complexity of diseases, the rise of personalized medicine, and the need for efficient, high-throughput testing methods are driving the growing global demand for multiplex assays.
"By product & service, the consumables segment is predicted to showcase the highest CAGR during the forecast period."
The growth in this segment is primarily driven by the consistent need for multiplex assay kits, reagents, beads, primers, probes, and controls, all of which are essential for conducting analyses. The rising incidence of infectious diseases, cancers, and autoimmune conditions is expected to increase testing demand across various healthcare settings. This will boost demand for the segment in hospitals, diagnostic labs, and research facilities. Additionally, the expanding use of multiplex testing protocols and the development of new assays will further contribute to this growth.
"By technology, the Flow cytometry segment is projected to hold the largest share of the multiplex assay market in 2026."
This market segment is dominant due to the widespread adoption of technology in hospitals and reference laboratories, enabling high-throughput and multiparametric testing with improved sensitivity, accuracy, and reproducibility in biomarker and cell analysis. Flow cytometry is among the most widely used instruments in immunology, oncology, and translational research, owing to its ability to rapidly analyze multiple markers in a single test. The demand for flow cytometers is primarily driven by the increasing number of diagnostic tests, scientific studies, and the need for disease profiling and therapy monitoring.
"The Asia Pacific is expected to register the fastest growth rate in the multiplex assay market."
This region is experiencing rapid growth due to several factors, including the expansion of healthcare facilities and increased healthcare spending. The modernization of hospitals, laboratories, and diagnostic centers is also contributing to this growth. Additionally, the rising incidence of infectious diseases, cancer, and chronic conditions is driving the demand for advanced diagnostic tests. Furthermore, increased investments in biotechnology research, the expansion of pharmaceutical production facilities, and a growing number of diagnostic centers are fueling the growth of multiplex assays in the Asia Pacific region. Key countries contributing to this market growth include China, India, Japan, and South Korea, among others.
The break-up of the profile of primary participants in the multiplex assay market:
- By Company Type: Tier 1 (35%), Tier 2 (40%), and Tier 3 (15%)
- By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
- By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
The key players in the multiplex assay market are Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Danaher Corporation (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), DiaSorin S.p.A. (Italy), Revvity, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies (US), Quanterix Corporation (US), and bioMerieux (France).
Research Coverage:
This research report categorizes the multiplex assay market by product & service (consumables, instruments, software & services), type (protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays), technology (flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), other technologies), application (research & development, clinical diagnostics), end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, contract research organizations, other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the multiplex assay market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the multiplex assay market. This report covers the competitive analysis of upcoming startups in the multiplex assay market ecosystem.
Reasons to buy this report:
The report will help market leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall multiplex assay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising incidence of chronic and infectious diseases, advantages over singleplex and traditional assays, increasing use of multiplex assays in companion diagnostics, growing focus on early disease detection, rising incidence of chronic and infectious diseases), restraints (cost constraints associated with multiplex assay instrumentation, regulatory challenges and stringent quality standards), opportunities (growing validation of biomarkers in molecular and protein-based diagnostics, advancements in biomarker validation in molecular and protein diagnostics, expansion in emerging markets), and challenges (shortage of skilled professionals, complex data analysis and interpretation).
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assay market.
- Market Development: Comprehensive information about lucrative markets; the report analyses the multiplex assay market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiplex assay market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific, Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), and bioMerieux (France).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN MULTIPLEX ASSAY MARKET
- 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MULTIPLEX ASSAY MARKET
- 3.2 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
- 3.3 MULTIPLEX ASSAY MARKET, BY TYPE, 2026 VS. 2031
- 3.4 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031
- 3.5 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2026 VS. 2031
- 3.6 MULTIPLEX ASSAY MARKET, BY END USER, 2026 VS. 2031
- 3.7 MULTIPLEX ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Rising incidence of chronic and infectious diseases
- 4.2.1.2 Advantages over singleplex and traditional assays
- 4.2.1.3 Increasing use of multiplex assays in companion diagnostics
- 4.2.1.4 Growing focus on early disease detection
- 4.2.1.5 Expansion of biomarker-driven research
- 4.2.2 RESTRAINTS
- 4.2.2.1 Cost constraints associated with multiplex assay instrumentation
- 4.2.2.2 Regulatory challenges and stringent quality standards
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Growing validation of biomarkers in molecular and protein-based diagnostics
- 4.2.3.2 Expansion in emerging markets
- 4.2.4 CHALLENGES
- 4.2.4.1 Shortage of skilled professionals
- 4.2.4.2 Complex data analysis and interpretation
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.3.1 UNMET NEEDS IN MULTIPLEX ASSAY MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
- 4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 MULTIPLEX ASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024-2026
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 3822)
- 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES AND EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.10 INVESTMENT AND FUNDING SCENARIO
- 5.11 IMPACT OF 2025 US TARIFF ON MULTIPLEX ASSAY MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON REGION
- 5.11.4.1 North America
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END-USE INDUSTRIES
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 MULTIPLEX REAL-TIME PCR
- 6.1.2 FLOW CYTOMETRY
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 BIOINFORMATICS
- 6.2.2 MICROFLUIDICS
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 NEXT-GENERATION SEQUENCING
- 6.3.2 DIGITAL PCR
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 LIST OF KEY PATENTS
- 6.6 FUTURE APPLICATIONS
- 6.7 IMPACT OF AI/GENERATIVE AI ON MULTIPLEX ASSAY MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 TOP USE CASES AND MARKET POTENTIAL
- 6.7.3 KEY COMPANIES IMPLEMENTING AI
- 6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS
- 7.2.1.1 Eco-friendly initiatives
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS
- 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
- 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
- 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE
- 9.1 INTRODUCTION
- 9.2 CONSUMABLES
- 9.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
- 9.3 INSTRUMENTS
- 9.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
- 9.4 SOFTWARE & SERVICES
- 9.4.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
10 MULTIPLEX ASSAY MARKET, BY TYPE
- 10.1 INTRODUCTION
- 10.2 PROTEIN MULTIPLEX ASSAYS
- 10.2.1 BEAD-BASED PROTEIN ASSAYS
- 10.2.1.1 Best suited to study protein-protein interactions
- 10.2.2 PLANAR PROTEIN ASSAYS
- 10.2.2.1 Pivotal role in drug discovery to support uptake
- 10.2.3 OTHER PROTEIN ASSAYS
- 10.2.1 BEAD-BASED PROTEIN ASSAYS
- 10.3 NUCLEIC ACID MULTIPLEX ASSAYS
- 10.3.1 BEAD-BASED NUCLEIC ACID ASSAYS
- 10.3.1.1 Increasing infectious diseases and genetic screening tests to drive market
- 10.3.2 PLANAR NUCLEIC ACID ASSAYS
- 10.3.2.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
- 10.3.3 OTHER NUCLEIC ACID ASSAYS
- 10.3.1 BEAD-BASED NUCLEIC ACID ASSAYS
- 10.4 CELL-BASED MULTIPLEX ASSAYS
- 10.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
11 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY
- 11.1 INTRODUCTION
- 11.2 FLOW CYTOMETRY
- 11.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO DRIVE SEGMENT
- 11.3 FLUORESCENCE DETECTION
- 11.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL SEGMENT GROWTH
- 11.4 MULTIPLEX REAL-TIME PCR
- 11.4.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
- 11.5 LUMINESCENCE
- 11.5.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
- 11.6 NEXT-GENERATION SEQUENCING (NGS)
- 11.6.1 RISING ADOPTION OF CUSTOMIZED AND APPLICATION-SPECIFIC NGS MULTIPLEX PANELS TO DRIVE MARKET
- 11.7 OTHER TECHNOLOGIES
12 MULTIPLEX ASSAY MARKET, BY APPLICATION
- 12.1 INTRODUCTION
- 12.2 RESEARCH & DEVELOPMENT
- 12.2.1 DRUG DISCOVERY & DEVELOPMENT
- 12.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
- 12.2.2 BIOMARKER DISCOVERY & VALIDATION
- 12.2.2.1 Advancing biomarker discovery through global collaborative research networks
- 12.2.1 DRUG DISCOVERY & DEVELOPMENT
- 12.3 CLINICAL DIAGNOSTICS
- 12.3.1 INFECTIOUS DISEASES
- 12.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
- 12.3.2 CANCER
- 12.3.2.1 Rising burden of cancer to drive market
- 12.3.3 CARDIOVASCULAR DISEASES
- 12.3.3.1 High burden of cardiovascular diseases to support market growth
- 12.3.4 AUTOIMMUNE DISEASES
- 12.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
- 12.3.5 NERVOUS SYSTEM DISORDERS
- 12.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
- 12.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
- 12.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers help in timely diagnosis
- 12.3.7 OTHER DISEASES
- 12.3.1 INFECTIOUS DISEASES
13 MULTIPLEX ASSAY MARKET, BY END USER
- 13.1 INTRODUCTION
- 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 13.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE MARKET
- 13.3 HOSPITALS & DIAGNOSTIC LABORATORIES
- 13.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
- 13.4 ACADEMIC & RESEARCH INSTITUTES
- 13.4.1 RISING GOVERNMENT FUNDING TO ACCELERATE MULTIPLEX ADOPTION IN ACADEMIC RESEARCH
- 13.5 CONTRACT RESEARCH ORGANIZATIONS
- 13.5.1 RISING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES TO ACCELERATE MULTIPLEX ASSAY ADOPTION AMONG CROS
- 13.6 OTHER END USERS
14 MULTIPLEX ASSAY MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 US
- 14.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market
- 14.2.2 CANADA
- 14.2.2.1 Favorable government initiatives to fuel market
- 14.2.1 US
- 14.3 EUROPE
- 14.3.1 GERMANY
- 14.3.1.1 Strong healthcare infrastructure to drive market
- 14.3.2 UK
- 14.3.2.1 Expansion of diagnostic infrastructure to drive market
- 14.3.3 FRANCE
- 14.3.3.1 Strong R&D investments and growing disease burden to drive market
- 14.3.4 ITALY
- 14.3.4.1 Growing adoption of advanced diagnostics to drive market
- 14.3.5 SPAIN
- 14.3.5.1 Rising disease burden to drive market
- 14.3.6 REST OF EUROPE
- 14.3.1 GERMANY
- 14.4 ASIA PACIFIC
- 14.4.1 CHINA
- 14.4.1.1 Strong healthcare investments to drive market
- 14.4.2 JAPAN
- 14.4.2.1 Universal healthcare reimbursement policy to foster market growth
- 14.4.3 INDIA
- 14.4.3.1 Increased private and public investments to bolster growth
- 14.4.4 REST OF ASIA PACIFIC
- 14.4.1 CHINA
- 14.5 LATIN AMERICA
- 14.5.1 BRAZIL
- 14.5.1.1 Rising disease burden and expanding research ecosystem to drive market
- 14.5.2 MEXICO
- 14.5.2.1 Rising chronic disease burden to drive market
- 14.5.3 REST OF LATIN AMERICA
- 14.5.1 BRAZIL
- 14.6 MIDDLE EAST & AFRICA
- 14.6.1 GROWING HEALTHCARE INVESTMENTS AND RISING DEMAND FOR MULTIPLEX TESTING TO DRIVE MARKET
15 COMPETITIVE LANDSCAPE
- 15.1 INTRODUCTION
- 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023-2026
- 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MULTIPLEX ASSAY MARKET
- 15.3 REVENUE ANALYSIS, 2023-2025
- 15.4 MARKET SHARE ANALYSIS, 2025
- 15.4.1 MARKET SHARE ANALYSIS, 2025
- 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 15.5.5.1 Company footprint
- 15.5.5.2 Region footprint
- 15.5.5.3 Product & service footprint
- 15.5.5.4 Application footprint
- 15.5.5.5 End user footprint
- 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.1 PROGRESSIVE COMPANIES
- 15.6.2 RESPONSIVE COMPANIES
- 15.6.3 DYNAMIC COMPANIES
- 15.6.4 STARTING BLOCKS
- 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.5.1 Detailed list of key startups/SMEs
- 15.6.5.2 Competitive benchmarking of key startups/SMEs (1/2)
- 15.6.5.3 Competitive benchmarking of key startups/SMEs (2/2)
- 15.7 COMPANY VALUATION AND FINANCIAL METRICS
- 15.7.1 FINANCIAL METRICS
- 15.7.2 COMPANY VALUATION
- 15.8 BRAND/PRODUCT COMPARISON
- 15.9 COMPETITIVE SCENARIO
- 15.9.1 PRODUCT LAUNCHES & APPROVALS
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
16 COMPANY PROFILES
- 16.1 KEY PLAYERS
- 16.1.1 ILLUMINA, INC.
- 16.1.1.1 Business overview
- 16.1.1.2 Products offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product launches & approvals
- 16.1.1.3.2 Deals
- 16.1.1.4 MnM view
- 16.1.1.4.1 Right to win
- 16.1.1.4.2 Strategic choices
- 16.1.1.4.3 Weaknesses & competitive threats
- 16.1.2 BIO-RAD LABORATORIES, INC.
- 16.1.2.1 Business overview
- 16.1.2.2 Products offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Product launches & approvals
- 16.1.2.3.2 Deals
- 16.1.2.4 MnM view
- 16.1.2.4.1 Right to win
- 16.1.2.4.2 Strategic choices
- 16.1.2.4.3 Weaknesses & competitive threats
- 16.1.3 THERMO FISHER SCIENTIFIC INC.
- 16.1.3.1 Business overview
- 16.1.3.2 Products offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Product launches & approvals
- 16.1.3.3.2 Deals
- 16.1.3.4 MnM view
- 16.1.3.4.1 Right to win
- 16.1.3.4.2 Strategic choices
- 16.1.3.4.3 Weaknesses & competitive threats
- 16.1.4 DIASORIN S.P.A.
- 16.1.4.1 Business overview
- 16.1.4.2 Products offered
- 16.1.4.3 Recent developments
- 16.1.4.3.1 Product launches & approvals
- 16.1.4.3.2 Deals
- 16.1.4.4 MnM view
- 16.1.4.4.1 Right to win
- 16.1.4.4.2 Strategic choices
- 16.1.4.4.3 Weaknesses & competitive threats
- 16.1.5 BIOMERIEUX
- 16.1.5.1 Business overview
- 16.1.5.2 Products offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Product launches & approvals
- 16.1.5.3.2 Deals
- 16.1.5.4 MnM view
- 16.1.5.4.1 Right to win
- 16.1.5.4.2 Strategic choices
- 16.1.5.4.3 Weaknesses & competitive threats
- 16.1.6 BECTON, DICKINSON AND COMPANY
- 16.1.6.1 Business overview
- 16.1.6.2 Products offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Product launches & approvals
- 16.1.6.3.2 Deals
- 16.1.7 QIAGEN N.V.
- 16.1.7.1 Business overview
- 16.1.7.2 Products offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Product launches & approvals
- 16.1.7.3.2 Deals
- 16.1.8 MERCK KGAA
- 16.1.8.1 Business overview
- 16.1.8.2 Products offered
- 16.1.8.3 Recent developments
- 16.1.8.3.1 Deals
- 16.1.8.3.2 Expansions
- 16.1.9 AGILENT TECHNOLOGIES, INC.
- 16.1.9.1 Business overview
- 16.1.9.2 Products offered
- 16.1.9.3 Recent developments
- 16.1.9.3.1 Product launches & approvals
- 16.1.9.3.2 Deals
- 16.1.10 DANAHER CORPORATION
- 16.1.10.1 Business overview
- 16.1.10.2 Products offered
- 16.1.10.3 Recent developments
- 16.1.10.3.1 Product launches & approvals
- 16.1.10.3.2 Deals
- 16.1.11 REVVITY, INC.
- 16.1.11.1 Business overview
- 16.1.11.2 Products offered
- 16.1.11.3 Recent developments
- 16.1.11.3.1 Product launches & approvals
- 16.1.11.3.2 Deals
- 16.1.12 F. HOFFMANN-LA ROCHE LTD
- 16.1.12.1 Business overview
- 16.1.12.2 Products offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Product launches & approvals
- 16.1.12.3.2 Deals
- 16.1.13 QUANTERIX CORPORATION
- 16.1.13.1 Business overview
- 16.1.13.2 Products offered
- 16.1.13.3 Recent developments
- 16.1.13.3.1 Product launches & approvals
- 16.1.13.3.2 Deals
- 16.1.1 ILLUMINA, INC.
- 16.2 OTHER PLAYERS
- 16.2.1 BIO-TECHNE CORPORATION
- 16.2.2 SEEGENE INC.
- 16.2.3 MESO SCALE DIAGNOSTICS LLC
- 16.2.4 RANDOX LABORATORIES LTD.
- 16.2.5 STANDARD BIOTOOLS INC.
- 16.2.6 HOLOGIC, INC.
- 16.2.7 ABBOTT LABORATORIES
- 16.2.8 SIEMENS HEALTHINEERS AG
- 16.2.9 ENZO BIOCHEM INC.
- 16.2.10 SHIMADZU CORPORATION
- 16.2.11 PROMEGA CORPORATION
- 16.2.12 BOSTER BIOLOGICAL TECHNOLOGY
17 RESEARCH METHODOLOGY
- 17.1 RESEARCH DATA
- 17.1.1 SECONDARY RESEARCH
- 17.1.1.1 Key data from secondary sources
- 17.1.2 PRIMARY DATA
- 17.1.2.1 Primary sources
- 17.1.2.2 Key data from primary sources
- 17.1.2.3 Key industry insights
- 17.1.1 SECONDARY RESEARCH
- 17.2 MARKET SIZE ESTIMATION
- 17.2.1 BOTTOM-UP APPROACH
- 17.2.1.1 Approach 1: Company revenue estimation approach
- 17.2.1.2 Approach 2: Presentations of companies and primary interviews
- 17.2.1.3 Growth forecast
- 17.2.2 TOP-DOWN APPROACH
- 17.2.1 BOTTOM-UP APPROACH
- 17.3 MARKET BREAKDOWN AND DATA TRIANGULATION
- 17.4 MARKET SHARE ANALYSIS
- 17.5 RESEARCH ASSUMPTIONS
- 17.5.1 PARAMETRIC ASSUMPTIONS
- 17.5.2 GROWTH RATE ASSUMPTIONS
- 17.6 RESEARCH LIMITATIONS
- 17.7 RISK ASSESSMENT
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS
